Marrone Bio Innovations Inc (NASDAQ:MBII) Institutional Investor Sentiment Is 5.83

September 14, 2018 - By Kristin Houston

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Logo

Sentiment for Marrone Bio Innovations Inc (NASDAQ:MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) institutional sentiment increased to 5.83 in Q2 2018. Its up 0.33, from 5.5 in 2018Q1. The ratio has improved, as 35 investment professionals started new or increased stock positions, while 6 sold and decreased stakes in Marrone Bio Innovations Inc. The investment professionals in our partner’s database now own: 51.29 million shares, down from 78.12 million shares in 2018Q1. Also, the number of investment professionals holding Marrone Bio Innovations Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 2 Increased: 8 New Position: 27.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $218.97 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The companyÂ’s products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

The stock decreased 1.98% or $0.04 during the last trading session, reaching $1.98. About 40,940 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 68.10% since September 14, 2017 and is uptrending. It has outperformed by 52.48% the S&P500.

Analysts await Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report earnings on November, 12. They expect $-0.04 earnings per share, up 85.19 % or $0.23 from last year’s $-0.27 per share. After $-0.04 actual earnings per share reported by Marrone Bio Innovations, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Ardsley Advisory Partners holds 2.02% of its portfolio in Marrone Bio Innovations, Inc. for 10.35 million shares. Icm Asset Management Inc Wa owns 250,000 shares or 0.4% of their US portfolio. Moreover, Waddell & Reed Financial Inc has 0.02% invested in the company for 4.71 million shares. The New York-based Spark Investment Management Llc has invested 0.01% in the stock. American International Group Inc, a New York-based fund reported 35,540 shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $49,900 activity.

More news for Marrone Bio Innovations, Inc. (NASDAQ:MBII) were recently published by: Nasdaq.com, which released: “Marrone Bio Innovations, Inc. to Present at the HC Wainwright 20th Annual Global Investment Conference in New York” on August 30, 2018. Nasdaq.com‘s article titled: “Marrone Bio Innovations Appoints Jenna Combs as Sales Manager of Northern California Territory” and published on September 11, 2018 is yet another important article.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.